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cu.2012.Abstract A new simple, accurate, precise, rapid and economical method was developed for the
simultaneous determination of Salmeterol xinafoate and Fluticasone propionate in their binary
mixture in bulk powder and Seritide diskus inhalation. The new method depends on new calcula-
tions using the mixture’s absorbance at 225 and 256.5 nm where the absorptivity of Salmeterol xin-
afoate is double the absorptivity of Fluticasone propionate, while the content of Salmeterol
xinafoate was determined by measuring the absolute value of the ﬁrst derivative ultraviolet curves
at 352 nm, without interference from Fluticasone propionate. The proposed method was validated
and the results obtained by adopting the proposed method were statistically analyzed and compared
with those obtained by reported methods.
ª 2012 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Salmeterol xinafoate and Fluticasone propionate are formu-
lated together in an inhalation known as Seritide Diskus
inhalation, used to treat asthma. Salmeterol xinafoate is
grouped in a class of medications called b2 adrenergic224761181.
(M. Abdelkawy).
Faculty of Pharmacy, Cairo
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, Cairo University. Production and
07.006receptors agonists. Fluticasone propionate is grouped in a class
of medications called corticosteroids. The combination of
Salmeterol xinafoate and Fluticasone propionate works by
reversing the bronchoconstriction occuring in asthma.
Salmeterol xinafoate was determined by several methods
including spectrophotometry1–3, HPTLC4 HPLC5–7 and elec-
trophoresis.8 Fluticasone propionate was determined by spec-
trophotometric methods2,9,10 and by HPLC methods.6,7,11–13
The aim of this work, to develop newmethod that can be ap-
plied for the determination of the concentrations of two compo-
nent of different absorptivities in binarymixture, so this method
has advantage of wide application over the classical isoabsorp-
tive point method14–16 that restricted for the components of
similar absorptivities at certain point and to apply this method
for the simultaneous determination of salmeterol xinafoate andhosting by Elsevier B.V.Open access under CC BY-NC-ND license.
122 A. Samir et al.Fluticasone propionate in the mixture in Seritide Diskus inhala-
tion. The absorptivity factor is a novel method and it depends
on applying a simple mathematical equation to calculate the
concentration of both components in such a binary mixture.
In this mixture like many other mixtures there is a large differ-
ence in the absorptivity of each drug from the absorptivity of
the other so there is no isoabsorptive point occurs. In this case
the simultaneous determination of each drug in the presence of
the other can’t be carried out by applying the isoabsorptivity
technique. In this work a new method was developed by modi-
fying the classical isoabsorptivemethod. The newmethod called
absorptivity factor method can solve this problem and enable
the annalists to carry out the simultaneous determination of
such mixtures using zero order spectra of the mixture by substi-
tution in a simple equation without the need to use an advanced
software or to carry out several trials like those required in
aother spectrophotometric techniques. The aim of that work
is to use the newly developed method for the simultaneous
determination of salmeterol xinafoate and Fluticasone propio-
nate in the mixture in Seritide Diskus inhalation.2. Theory
For the two drugs X and Y, in the mixture, where concentra-
tion of Y can be determined by using any of the well estab-
lished spectrophotometric methods.
For the determination the concentration of X, The absorp-
tivity factor method is applied .This method depends on the
calculation of the absorptivity factor which is the ratio be-
tween the two absorptivities (ax, aY) at intersection point with
the same absorbance value. This point is called the absorbtiv-
ity factor point (kF). This is summarized as follows:
Ax ¼ Ay
axbxCx ¼ aybyCy
Where bx ¼ by ¼ 1Cm
axCx ¼ ayCy
ax=ay ¼ Cy=Cx
ax=ay ¼ F
ax ¼ Fay
where, F is the absorptivity factor, ax, aY are the absorptivities
of X and Y’ respectively.
For mixture of X and Y the total absorbance of X and Y at
absorptivity factor point kF can be expressed as follows:
Am ¼ Ax þ Ay
Am ¼ axbxCx þ aybyCy ðWhere bx ¼ by ¼ 1CmÞ
Am ¼ axCx þ ayCy
where AX, Ay and Am are the absorbance of X, Y and their
mixture at kF respectively Cx and CY are the concentrations
of X and Y respectively ax and aY are the absorptivities of X
and Y at kF respectively. ax is substituted by Fay
Am ¼ ayFCx þ ayCy
Am ¼ ayðFCx þ CyÞ
So, the total concentration of the mixture(FCx + CY) can be
calculated by using a regression equation representing the lin-
ear relationship between the absorbance of Y and its corre-
sponding concentration at the absorptivity factor point.The concentration of X can be determined after subtrac-
tion of concentration of Y and multiplication by the inverse
of F
ðFCx þ CyÞ  Cy
Cx ¼ FCx  1=F3. Experimental
3.1. Apparatus
UV–Visible spectrophotometer, Shimadzu UV-1800. con-
nected to an IBM compatible computer. The software was
UVPC personal spectroscopy software version 3.7 (Shimadzu).
The absorption spectra of the reference and test solutions were
carried out in 1 cm quartz cells.
3.2. Chemicals and pharmaceutical preparation
- Salmeterol xinafoate pure sample was kindly provided by
ADCO Co., Cairo, Egypt while Fluticasone propionate
pure sample was kindly provided by Galaxo Wellcome,
Cairo, Egypt. their percentage purity was certiﬁed to be
99.87 ± 0.342 and 100.31 ± 0.52, respectively.
- Seritide diskus inhaler batch No. R467369 (Galaxo-
SmithKline group) purchased from Egyptian market
labeled to contain 50 lg Salmeterol xinafoate and 100 lg
Fluticasone propionate/dose.3.3. Standard stock and working solutions
Stock standard solutions of Salmeterol xinafoate and Flutica-
sone propionate were prepared separately by dissolving 40 mg
of each drug in methanol and completing the volume to
100 mL using the same solvent. Working stock solutions were
prepared by diluting 20 mL of each stock solution to 100 mL
in a volumetric ﬂask using the same solvent to get working
solutions containing 80 lg/mL of Salmeterol xinafoate or Flu-
ticasone propionate. Series of concentration of each drug is
prepared by diluting this working solutions in a series of
10 mL volumetric ﬂasks to obtain a concentration range of
4–60 lg/mL for Salmeterol xinafoate and 4–28 lg/mL for Flu-
ticasone propionate.
3.4. Analysis of laboratory prepared mixtures
From the ﬁrst derivative spectra of the laboratory prepared
mixtures the concentration of Salmeterol xinafoate obtained
at 352 nm by substituting in regression equation, the corre-
sponding concentration of Fluticasone propionate is obtained
by subtracting the concentration of Salmeterol xinafoate from
the results obtained by substitution in regression equations at
absorptivity factor points (225 nm and 256.5 nm) then multi-
plying by two.
4. Results and discussion
4.1. Method of analysis
The zero order absorption spectra of 8 lg mL1 of Salmeter-
ol xinafoate and 16 lg mL1 of Fluticasone propionate were
Figure 1 The Zero order spectra of 8 lg/mL Salmeterol xinafo-
ate and 16 lg/mL Fluticasone propionate showing the absorptiv-
ity factor points.
Figure 2 Calibration curves of Salmeterol Xinafoate at 225,
256.5.
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Figure 3 First derivative spectra of Salmeterol xinafoate (12–
60 lg/mL), Dk= 4 nm showing a peak at 352 nm.
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Figure 4 Calibration curve of ﬁrst derivative spectra of Salme-
terol xinafoate at 352 nm, Dk= 4 nm.
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the absorptivity of Salmeterol xinafoate is double that of the
Fluticasone propionate (F=½) to construct the calibration
curve of Salmeterol xinafoate at chosen absorptivity factor
points 225 and 256.5 nm (Fig. 2). For this mixture absorp-
tivity of salmeterol xinafoate can be determined without
the interference of Fluticasone propionate by ﬁrst derivative
spectra at 352 nm (Fig. 3) so the calibration curve of the
ﬁrst derivative spectra of salmeterol xinafoate is also con-structed at 352 nm taking Dk equals 4 nm (Fig. 4).the con-
centration of Fluticasone propionate is then calculated by
subtraction and multiplying by 1/F. This method is consid-
ered as a modiﬁcation of isoabsorptive technique14–16 but
in the isoabsorptive technique the spectra of the same con-
centration of the two studied drugs should cross at a point
called isoabsorptivity point at which they have equal absorp-
tivities while in absorpitivity factor method the crossing
point did not occur at equal concentration so the crossing
point is obtained between different concentrations of the
two drugs. At this point the absorptivities of the two drugs
are not equal but they are equal to the inverse of the ratio
of the used concentrations.
4.2. Mixture analysis
The ﬁrst derivative spectra of the mixture spectra are found
and the concentration of salmeterol xinafoate is found by sub-
stitution in the ﬁrst derivative linearity equation at 352 nm.
Then by using the zero order values at 225 and 256.5 nm the
sum of salmeterol xinafoate and half the concentration of Flu-
ticasone propionate can be found by substitution in zero order
linearity equations of salmeterol xinafoate at those points, the
concentration of Fluticasone propionate can be calculated by
subtraction then multiplying by two
4.3. Analysis of pharmaceutical products
The proposed Absorptivity factor method was applied for the
simultaneous determination of Salmeterol xinafoate and Fluti-
casone propionate in Seritide Diskus inhaler. The perfor-
mance of the method was statistically compared with that of
a reported method6 by Student’s t-test and F-values at 95%
conﬁdence level. The calculated t and F-values did not exceed
the tabulated values (Table 6), indicating that there was no sig-
niﬁcant difference between the results of the developed and
those of the reported method.
4.4. Validation of the methods
4.4.1. Linearity
The linearity ranges for the determination of Salmeterol xinafo-
ate and Fluticasone propionate by the proposed method was
evaluated by analyzing a series of different concentrations of
each drug. Fluticasone propionate gave a linearity range 4–
28 lg/mL at chosen points while Salmeterol xinafoate gave a
linearity range 4–20 lg/mL at chosen points and 12–60 lg/mL
Table 1 Validation parameters of constructed calibration curves of Salmeterol xinafoate zero order spectra at 225 nm and 256.5 and
ﬁrst derivative at 352 nm.
SAM
k (nm) 352 (ﬁrst derivative) 225 256.5
Linearity range (lg/mL) 12–60 4–20 4–20
LOD (lg/mL) 0.022 0.101 0.104
Slope 0.00229 0.05745 0.03218
SE of slope 7.7E-06 0.000582 0.000335
Intercept 0.00109 0.0048 0.0021
SE of intercept 0.000304 0.007717 0.00444
r2 0.9999 0.9997 0.9997
r 1.000 0.9998 0.9998
Table 2 Precision of determination of Salmeterol xinafoate and Fluticasone propionate by the proposed and absorptivity factor
method.
Salmeterol xinafoate Fluticasone propionatea
352 nm (ﬁrst derivative) At 225 nm At 256.5 nm
8 lg/mL 12 lg/mL 20 lg/mL 8 lg/mL 12 lg/mL 20 lg/mL 8 lg/mL 12 lg/mL 20 lg/mL
Intraday 1 101.02 100.26 101.23 98.51 100.22 101.46 99.92 100.29 100.85
2 100.36 100.89 100.33 101.34 102.08 100.08 98.06 99.85 101.92
3 100.88 98.91 100.76 100.19 100.68 99.42 98.93 102.22 100.06
X 100.75 100.02 100.77 100.01 100.99 100.32 98.97 100.79 101.28
±SD 0.348 1.012 0.45 1.423 0.969 1.041 0.93 1.261 0.567
%RSD 0.351 1.012 0.453 1.423 0.979 1.044 0.920 1.271 0.574
Interday 1 100.72 100.69 99.52 100.22 100.89 99.65 100.82 99.85 98.93
2 100.96 100.85 101.35 99.07 101.35 99.65 101.42 102.04 100.25
3 98.42 101.68 101.02 99.57 100.66 101.06 100.74 100.26 99.77
X 100.03 101.07 100.63 99.62 100.97 100.12 100.99 100.72 99.65
±SD 1.402 0.531 0.975 0.577 0.351 0.814 0.372 1.164 0.668
%RSD 1.402 0.531 0.975 0.577 0.351 0.814 0.372 1.164 0.668
a After subtraction and multiplication by 2.
Table 3 Determination of Salmeterol xinafoate and Fluticasone propionate by the proposed absorptivity factor method.
Flu:Sam ratio Salmeterol xinafoate Fluticasone propionate
Taken
(lg/mL)
Found
(lg/mL)
% recovery Taken
(lg/mL)
Founda at
225 (lg/mL)
% recovery Founda at
256.5 (lg/mL)
% recovery
2.5:3 12 12.12 101.00 10 10.07 100.75 10.20 101.99
2:2 8 7.86 98.19 8 7.87 98.43 7.99 99.91
2:3 12 12.09 100.75 8 7.87 98.38 7.89 98.59
2:4 16 16.04 100.88 8 8.36 102.07 8.28 101.11
3:3 12 12.13 100.25 12 11.55 97.94 11.74 99.50
3:4 16 15.89 99.33 12 11.90 99.18 12.21 101.71
3:5 20 19.96 99.78 12 11.65 97.05 11.94 99.51
4:2 8 7.98 99.76 16 15.67 97.94 15.98 99.88
4:3 12 11.90 99.13 16 15.96 99.74 16.33 102.06
4:4 16 15.78 98.64 16 15.81 98.84 16.23 101.46
4:5 20 19.96 99.78 16 15.76 98.48 16.19 101.17
5:2 8 7.78 97.28 20 19.93 99.67 20.18 100.92
5:3 12 11.70 97.46 20 19.81 99.03 20.04 100.18
5:4 16 16.04 100.27 20 19.40 97.01 19.71 98.53
X 99.46 98.89 100.46
SD 1.202 1.369 1.189
%RSD 1.209 1.384 1.184
N 14.00 14.00 14.00
a After subtraction and multiplication by 2.
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Table 5 Statistical analysis of the results obtained by applying the proposed absorptivity factor method and the reported method for
the analysis of Salmeterol xinafoate and Fluticasone propionate pure samples.
Method Salmeterol xinafoate Fluticasone propionate
Reported method6 absorpativity Factor method Reported method6 absorpativity Factor method
k (nm) 352 (1st derivative) 225 256.5
X ± SDa 100.44 ± 0.502 100.29 ± 1.117 100.31 ± 0.719 99.83 ± 1.405 100.24 ± 0.605
N 5 5 5 5 5
t (2.306) 0.270 0.683 0.162
F (6.338) 4.951 3.818 1.412
**Eight degrees of freedom.
a Average of ﬁve determinations.
Table 4 Application of the standard addition technique for the determination of Salmeterol xinafoate and Fluticasone propionate in
their pharmaceutical dosage form by the proposed absorptivity factor method.
Salmeterol xinafoate Fluticasone propionate
Standard
added (lg/mL)
Found at
352a (lg/mL)
% recovery Standard added
(lg/mL)
Foundb at
225a (lg/mL)
% recovery Foundb at
256.5a (lg/mL)
% recovery
4 4.02 100.5 4 4.05 101.25 4.03 100.75
6 5.98 99.67 6 5.88 98 6.07 101.17
8 7.99 99.88 8 7.92 99 7.95 99.38
X 100.01 99.42 100.43
±SD 0.438 1.665 0.938
%RSD 0.438 1.675 0.934
N 9 9 9
a Average of three determinations.
b After subtraction and multiplication by 2.
Table 6 Statistical analysis of the results obtained by applying the proposed absorptivity factor method and the reported method for
the analysis of Salmeterol xinafoate and Fluticasone propionate in their pharmaceutical dosage form.
Method Salmeterol xinafoate Fluticasone propionate
Reported method6 absorpativity Factor method Reported method6 absorpativity Factor method
k (nm) 352 (1st derivative) 225 256.5
X ± SDa 100.29 ± 1.226 100.73 ± 1.298 100.58 ± 0.805 101.16 ± 1.313 100.57 ± 1.510
N 5 5 5 5 5
t (2.306)b 0.549 0.76 0.096
F (6.338) 1.120 2.660 3.519
a Average of ﬁve determinations.
b Eight degrees of freedom.
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peated three times; in order to provide information on spectro-
photometric values between samples of same concentration.
The linearity of the calculated graphs was validated by the high
value of the correlation coefﬁcient and law intercept value
(Table 1). Characteristic parameters for regression equations
of the studied methods obtained by least squares treatment of
the results are given in Table 1. The obtained calibration curves
of Salmeterol xinafoate at the absorptivity factor points (225
and 256.5 nm) are shown in Fig. 2 and the calibration curve
of the ﬁrst derivative spectra of salmeterol xinafoate at
352 nm is shown in Fig. 4.4.4.2. Detection limits
According to the International Conference on Harmonization
(ICH) recommendations, the approach based on the standard
deviation (SD) of the response and the slope was used for
determining the detection limits. The theoretical values for
the proposed methods were assessed practically and given in
Table 1.4.4.3. Precision
The precision of the methods was evaluated by calculating the
relative standard deviation of the interday and intraday assay
126 A. Samir et al.results. The mean relative standard deviations are presented in
Table 2 and can be considered to be satisfactory.
4.4.4. Selectivity
Method selectivity was achieved by preparing several labora-
tory-prepared mixtures of the studied compounds at various
concentrations within the linearity range. The laboratory-
prepared mixtures were analyzed according to the previous
procedure described under the proposed method. Satisfactory
results were obtained (Table 3) indicating the high selectivity
of the proposed method for the simultaneous determination
of Salmeterol xinafoate and Fluticasone propionate binary
mixture.
4.4.5. Accuracy
Accuracy of the method was determined by the analysis of
some salmeterol xinafoate and Fluticasone propionate pure
samples by the proposed absorptivity factor method and the
results were compared with the results obtained by a reported
method (Table 5). The interference of excipients in the phar-
maceutical formulations was studied by the absorptivity factor
method. For this reason, standard addition method was ap-
plied to the pharmaceutical formulation containing these
compounds. In the application of standard addition method
to the pharmaceutical formulation, the mean percentage recov-
eries and their standard deviation for the proposed method for
nine replicates were calculated (Table 4). According to the
obtained results the excipients in pharmaceutical formulation
do not interfere in the analysis of these compounds in the phar-
maceutical formulation.
5. Conclusion
For routine analytical purposes, it is always of interest to
establish methods capable of analyzing a large number of sam-
ples in a short time period with high accuracy and precision.
Spectrophotometric techniques can generate large amounts
of data within a short period of analysis, the developed absorp-
tivity factor method has many advantages as it is a novel spec-
trophotometric method and it depends on applying a simple
mathematical equation to calculate the concentration of both
components in the binary mixture with no need for a special
expensive software or an advanced expensive device, also it
doesnot need any special reagents or high grade solvents which
make it a simple, economic, and time saving method as well as
an accurate, precise, and problem solving method.
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